|
Jun 25
|
AstraZeneca’s trial of Imfinzi for lung cancer failed to meet primary endpoint
|
|
Jun 22
|
3 No-Brainer Stocks to Buy for Under $100 Right Now
|
|
Jun 21
|
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
|
|
Jun 21
|
AstraZeneca’s Truqap and Faslodex combo receives approval in EU
|
|
Jun 10
|
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
|
|
Jun 10
|
Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks
|
|
Jun 10
|
AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag
|
|
Jun 10
|
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
|
|
Jun 10
|
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
|
|
Jun 10
|
Most CEOs are defeating attempts to vote down their pay. Can Tesla's Elon Musk do the same?
|
|
Jun 7
|
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
|
|
Jun 7
|
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
|
|
Jun 6
|
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
|
|
Jun 5
|
AstraZeneca completes Fusion Pharmaceuticals acquisition
|
|
Apr 1
|
Astrazeneca (AZN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
|
|
Apr 1
|
VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
|
|
Apr 1
|
AstraZeneca PLC's (LON:AZN) Stock Is Going Strong: Have Financials A Role To Play?
|
|
Apr 1
|
AstraZeneca gets FDA OK for rare disease drug acquired in Alexion buyout
|
|
Mar 30
|
20 Countries with the Highest Age Dependency Ratio in the World
|
|
Mar 29
|
AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know
|